These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38843619)

  • 1. Randomized double-blind placebo-controlled trial of the effects of oral trehalose in spinocerebellar ataxia type 3: An interim analysis.
    Yap KH; Azmin S; Abdul Manan H; Yahya N; Ahmad N; Tajurudin FW; Mat Desa SH; van de Warrenburg B; Mohamed Mukari SA; Achok HN; Ahmad Damanhuri H; Rani R; Mohamed Ibrahim N
    Parkinsonism Relat Disord; 2024 Jul; 124():107013. PubMed ID: 38843619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebellar transcranial direct current stimulation in spinocerebellar ataxia type 3 (SCA3-tDCS): rationale and protocol of a randomized, double-blind, sham-controlled study.
    Maas RPPWM; Toni I; Doorduin J; Klockgether T; Schutter DJLG; van de Warrenburg BPC
    BMC Neurol; 2019 Jul; 19(1):149. PubMed ID: 31272408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral trehalose maybe helpful for patients with spinocerebellar ataxia 3 and should be better evaluated.
    Noorasyikin MA; Azizan EA; Teh PC; Farah Waheeda T; Siti Hajar MD; Long KC; Norlinah MI
    Parkinsonism Relat Disord; 2020 Jan; 70():42-44. PubMed ID: 31841943
    [No Abstract]   [Full Text] [Related]  

  • 4. Planning future clinical trials in Machado Joseph disease: Lessons from a phase 2 trial.
    Saute JA; Rieder CR; Castilhos RM; Monte TL; Schumacher-Schuh AF; Donis KC; D'Ávila R; Souza GN; Russo AD; Furtado GV; Gheno TC; Souza DO; Saraiva-Pereira ML; Portela LV; Camey S; Torman VB; Jardim LB
    J Neurol Sci; 2015 Nov; 358(1-2):72-6. PubMed ID: 26297649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia Type 3: a Randomized, Double-Blind, Sham-Controlled Trial.
    Maas RPPWM; Teerenstra S; Toni I; Klockgether T; Schutter DJLG; van de Warrenburg BPC
    Neurotherapeutics; 2022 Jul; 19(4):1259-1272. PubMed ID: 35501469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trehalose in Machado-Joseph Disease: Safety, Tolerability, and Efficacy.
    Zaltzman R; Elyoseph Z; Lev N; Gordon CR
    Cerebellum; 2020 Oct; 19(5):672-679. PubMed ID: 32514820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease.
    Saute JA; de Castilhos RM; Monte TL; Schumacher-Schuh AF; Donis KC; D'Ávila R; Souza GN; Russo AD; Furtado GV; Gheno TC; de Souza DO; Portela LV; Saraiva-Pereira ML; Camey SA; Torman VB; de Mello Rieder CR; Jardim LB
    Mov Disord; 2014 Apr; 29(4):568-73. PubMed ID: 24399647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of valproic acid treatment in SCA3/MJD patients.
    Lei LF; Yang GP; Wang JL; Chuang DM; Song WH; Tang BS; Jiang H
    Parkinsonism Relat Disord; 2016 May; 26():55-61. PubMed ID: 26997655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind crossover trial of trimethoprim-sulfamethoxazole in spinocerebellar ataxia type 3/Machado-Joseph disease.
    Schulte T; Mattern R; Berger K; Szymanski S; Klotz P; Kraus PH; Przuntek H; Schöls L
    Arch Neurol; 2001 Sep; 58(9):1451-7. PubMed ID: 11559318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term efficacy of repetitive transcranial magnetic stimulation in SCA3: A prospective, randomized, double-blind, sham-controlled study.
    Sikandar A; Liu XH; Xu HL; Li Y; Lin YQ; Chen XY; Li GH; Lin MT; Wang N; Chen WJ; Ni GX; Gan SR
    Parkinsonism Relat Disord; 2023 Jan; 106():105236. PubMed ID: 36529111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3.
    Zesiewicz TA; Greenstein PE; Sullivan KL; Wecker L; Miller A; Jahan I; Chen R; Perlman SL
    Neurology; 2012 Feb; 78(8):545-50. PubMed ID: 22323747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurocognitive Changes in Spinocerebellar Ataxia Type 3: A Systematic Review with a Narrative Design.
    Yap KH; Kessels RPC; Azmin S; van de Warrenburg B; Mohamed Ibrahim N
    Cerebellum; 2022 Apr; 21(2):314-327. PubMed ID: 34231180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative assessment of postural instability in spinocerebellar ataxia type 3 patients.
    Liu XH; Li Y; Xu HL; Sikandar A; Lin WH; Li GH; Li XF; Alimu A; Yu SB; Ye XH; Wang N; Ni J; Chen WJ; Gan SR
    Ann Clin Transl Neurol; 2020 Aug; 7(8):1360-1370. PubMed ID: 32638517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial.
    Coarelli G; Heinzmann A; Ewenczyk C; Fischer C; Chupin M; Monin ML; Hurmic H; Calvas F; Calvas P; Goizet C; Thobois S; Anheim M; Nguyen K; Devos D; Verny C; Ricigliano VAG; Mangin JF; Brice A; Tezenas du Montcel S; Durr A
    Lancet Neurol; 2022 Mar; 21(3):225-233. PubMed ID: 35063116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of Life since Pre-Ataxic Phases of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease.
    Bolzan G; Leotti VB; de Oliveira CM; Ecco G; Cappelli AH; Rocha AG; Kersting N; Rieck M; de Sena LS; Martins AC; Saraiva-Pereira ML; Jardim LB
    Cerebellum; 2022 Apr; 21(2):297-305. PubMed ID: 34231179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bidirectional Connections between Depression and Ataxia Severity in Spinocerebellar Ataxia Type 3 Patients.
    Lin MT; Yang JS; Chen PP; Qian MZ; Lin HX; Chen XP; Shang XJ; Wang DN; Chen YC; Jiang B; Chen YJ; Chen WJ; Wang N; Gan SR
    Eur Neurol; 2018; 79(5-6):266-271. PubMed ID: 29763923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.